Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type II - Overview
Neurofibromatoses Type II - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Neurofibromatoses Type II - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type II - Companies Involved in Therapeutics Development
AstraZeneca Plc
Beta Pharma Inc
BioXcel Corp
Millennium Pharmaceuticals Inc
Mulberry Biotherapeutics Inc
OncoTherapy Science Inc
Plex Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Neurofibromatoses Type II - Drug Profiles
Biologic for Neurofibromatosis Type II (NFII) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bortezomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brigatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icotinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-2282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neurofibromatoses Type II - Dormant Projects
Neurofibromatoses Type II - Product Development Milestones
Featured News & Press Releases
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Desigtion For AR-42
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Neurofibromatoses Type II, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Neurofibromatoses Type II, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Neurofibromatoses Type II - Pipeline by AstraZeneca Plc, 2021
Neurofibromatoses Type II - Pipeline by Beta Pharma Inc, 2021
Neurofibromatoses Type II - Pipeline by BioXcel Corp, 2021
Neurofibromatoses Type II - Pipeline by Millennium Pharmaceuticals Inc, 2021
Neurofibromatoses Type II - Pipeline by Mulberry Biotherapeutics Inc, 2021
Neurofibromatoses Type II - Pipeline by OncoTherapy Science Inc, 2021
Neurofibromatoses Type II - Pipeline by Plex Pharmaceuticals Inc, 2021
Neurofibromatoses Type II - Pipeline by Recursion Pharmaceuticals Inc, 2021
Neurofibromatoses Type II - Dormant Projects, 2021